Masaru Matsuda Sells $1.41M of Arcutis Biotherapeutics Inc (ARQT) — SEC Form 4, Nov 04, 2026
Open-Market Net Sale · SEC Form 4
−$1,411,513
10b5-1 Plan (Partial)
Equity position changed by -1.1%
Equity Position
111K sh
112,508 → 111,289
Equity Change
-1.1%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Masaru Matsuda CIK 0001798679 |
GC
|
Masaru Matsuda at Arcutis Biotherapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$3,441,287
More from this insider at Arcutis Biotherapeutics Inc
| 2026-09-18 | Sell | -$91,853 | View |
| 2026-09-10 | Sell | -$249,986 | View |
| 2026-08-06 | Sell | -$32,124 | View |
| 2026-05-06 | Sell | -$192,415 | View |
| 2026-03-04 | Sell | -$313,877 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2 | 2026-11-02 | S - Sale | 1,219 D | $31.86 | -$38,841 | 111,289 | Direct |
| Common StockF3 | 2026-11-04 | M - Exercise 10b5-1 | 40,000 A | $3.64 | +$145,600 | 151,289 | Direct |
| Common StockF3F4 | 2026-11-04 | S - Sale 10b5-1 | 40,000 D | $34.32 | -$1,372,672 | 111,289 | Direct |
Derivative Securities Transactions
Footnotes (5)
- F1
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Show more
- F2
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $31.57 to $32.23, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F3
- The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027. Show more
- F4
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $34.00 to $37.7966, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
- F5
- 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Show more
Related filings at Arcutis Biotherapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
273
institutional managers reporting a position
Largest by reported value
5%+ Holders · 13D/G
6 filers
-
Black Rock, Inc. 14.1%
Other insiders at Arcutis Biotherapeutics Inc
-
Patrick Burnett -$30K
-
Todd Watanabe -$139K
-
Howard G. Welgus -$127K
-
Howard G. Welgus -$114K
GET /v1/forms/4/0001628280-26-070385
API docs
View Original SEC Filing